Yuriy Ostapenko

机构：National Cancer Institute

发表论文 19 篇 · 总被引 3754 次 · h-index 8

代表论文

• Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma (2022 · NEJM Evidence · 被引 1529)
• Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial (2020 · The Lancet Oncology · 被引 706)
• Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial (2023 · The Lancet Oncology · 被引 698)
• Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial (2023 · The Lancet · 被引 514)
• Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC (2025 · Journal of Hepatology · 被引 155)
• Pembrolizumab in HER2-Positive Gastric Cancer (2024 · New England Journal of Medicine · 被引 74)